Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer

Weniger M., Moir J., Damm M., Maggino L., Kordes M., Rosendahl J., ...Daha Fazla

PANCREATOLOGY, cilt.20, sa.6, ss.1131-1138, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Sayı: 6
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.pan.2020.06.012
  • Dergi Adı: PANCREATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.1131-1138
  • Anahtar Kelimeler: FOLFIRINOX, Gemcitabine, Nab-paclitaxel, Neoadjuvant chemotherapy, ADJUVANT CHEMOTHERAPY, OPEN-LABEL, GEMCITABINE, FOLFIRINOX, RESECTION, ADENOCARCINOMA, PHASE-3, DEATHS
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Background: Neoadjuvant chemotherapy has become a powerful tool to convert borderline resectable (BRPC) and locally advanced pancreatic cancers (LAPC) into a resectable scenario. However, data analyzing the optimal type of therapy are scarce. In the present multicenter retrospective study, we evaluated the influence of FOLFIRINOX (FFX) and gemcitabine (GEM)-based neoadjuvant therapy on patient prognosis.